ApoB Test

Your standard cholesterol test tells you how much cholesterol is riding inside your LDL particles. But it does not tell you how many of those particles are floating through your bloodstream. That distinction matters more than most people realize, because it is the number of particles, not the amount of cholesterol they carry, that determines how many get trapped in your artery walls and start the process that leads to heart attacks and strokes.

ApoB (apolipoprotein B) is a large protein that wraps around every one of these artery-damaging particles. Each particle carries exactly one ApoB molecule, so measuring ApoB in your blood gives you a precise particle count. When your ApoB is high, you have more particles that can burrow into your artery walls, regardless of what your LDL cholesterol number says.

Why ApoB Outperforms Standard Cholesterol Testing

Standard LDL cholesterol (LDL-C) measures the total mass of cholesterol packed inside LDL particles. The problem is that LDL particles come in different sizes and carry different amounts of cholesterol. Two people with identical LDL-C numbers can have dramatically different numbers of actual particles. The person with smaller, cholesterol-depleted particles has more of them, more ApoB, and more risk.

This mismatch between LDL-C and actual particle count, called discordance, is surprisingly common. About 1 in 10 people have significantly more ApoB than their LDL-C would predict. In a study of over 95,000 adults from the Copenhagen General Population Study, those with excess ApoB had roughly 50% higher risk of heart attack and 35% higher risk of cardiovascular disease beyond what LDL-C alone predicted. This elevated risk held true across the entire LDL-C spectrum, including in people whose LDL-C looked low.

The discordance is especially pronounced in people with diabetes, metabolic syndrome, obesity, or triglycerides above 150 mg/dL. In these conditions, the liver produces more small, cholesterol-depleted LDL particles. Your LDL-C looks fine, but your arteries are getting bombarded with particles. ApoB catches this blind spot.

Heart Attack and Stroke Risk

The evidence linking ApoB to cardiovascular events is extensive and consistent across populations. When researchers account for both ApoB and LDL-C simultaneously, ApoB is the marker that retains its predictive power. In primary prevention, each standard deviation increase in ApoB was associated with a 27% higher risk of heart attack (HR 1.27) after adjusting for other lipid measures. LDL-C lost its independent association once ApoB was in the model.

Sources: Johannesen et al. (JACC, 2024); Pencina et al. (Clinical Chemistry, 2023); Johannesen et al. (Annals of Neurology, 2022).

What this means for you: ApoB predicts your risk of both heart attack and stroke more accurately than LDL-C. If you have metabolic risk factors like elevated triglycerides, insulin resistance, or excess body fat, the gap between what LDL-C tells you and what ApoB reveals can be clinically significant. Knowing your ApoB helps you and your clinician decide whether your current treatment is truly reducing your particle burden, or just making your cholesterol numbers look reassuring.

The Long Game: Risk Accumulates Over Decades

Atherosclerosis is not a disease that appears suddenly. It builds quietly over years and decades. Data from the Swedish AMORIS cohort, which followed over 137,000 adults for an average of 17.8 years, found that elevated ApoB (and the ApoB/ApoA1 ratio) was detectable roughly 20 years before cardiovascular events occurred. People in the highest tenth of the ApoB/ApoA1 ratio had 2.7 times the risk of heart attack compared to those in the lowest tenth.

Genetic studies reinforce this long-term picture. Using a technique called Mendelian randomization, which uses inherited genetic variants to mimic a lifelong clinical trial, researchers found that ApoB has a continuous, dose-dependent relationship with both coronary artery disease and death. There was no lower threshold below which further ApoB reduction stopped being beneficial. When researchers accounted for ApoB, LDL-C, and triglycerides together, only ApoB retained a strong independent effect on coronary disease risk (OR 1.92).

Residual Risk on Statin Therapy

If you are already taking a statin and your LDL-C is at goal, you might assume your lipid risk is managed. But statins lower LDL-C more than they lower ApoB, because statins preferentially clear larger, cholesterol-rich particles via LDL receptors on the liver. The remaining smaller particles carry less cholesterol each but are still counted by ApoB.

In statin-treated patients, ApoB and non-HDL-C continue to show clear dose-response relationships with heart attack and death, while LDL-C does not. When ApoB is high but LDL-C is at target, cardiovascular risk follows ApoB, not LDL-C. The 2026 ACC/AHA guidelines now recommend measuring ApoB in statin-treated patients with established cardiovascular disease, diabetes, or elevated triglycerides to guide decisions about adding further therapy.

Reference Ranges and Treatment Targets

ApoB levels vary by age, sex, and metabolic status. Men generally have higher levels than premenopausal women, though women's levels rise after menopause and converge with men's by about age 50 to 55. Body fat, diet, and kidney function also influence where your number falls. The table below summarizes treatment targets from current guidelines, organized by cardiovascular risk level.

Sources: National Lipid Association (2024); AACE/ACE (2017); 2026 ACC/AHA Guidelines.

These thresholds are drawn from major guideline bodies and represent clinical consensus. Some preventive cardiologists target even lower levels based on Mendelian randomization data showing no lower threshold for benefit. For context, PCSK9 inhibitor trials achieved median ApoB levels around 38 to 49 mg/dL, well below traditional targets, with continued cardiovascular benefit.

Your lab may report slightly different reference ranges depending on the assay used. The most meaningful comparison is always your own trend over time within the same lab, rather than a single reading compared to a population cutpoint.

Inherited Lipid Disorders

ApoB testing can help identify inherited conditions that dramatically raise cardiovascular risk. Familial combined hyperlipidemia, which produces elevated ApoB with mixed lipid elevations, is one of the most common inherited lipid disorders and strongly associated with premature heart disease. An ApoB level of 140 mg/dL or higher, particularly with LDL-C above 190 mg/dL, raises suspicion for familial hypercholesterolemia. About 2.5% of people with these levels carry a genetic variant that, once identified, can prompt cascade screening of family members and earlier, more aggressive treatment.

Why a Single Reading Is Not Enough

ApoB has a biological variability of about 6 to 7% in the same person from one draw to the next. That is relatively low compared to triglycerides (which can swing 17 to 28%), but it still means a single measurement can land slightly above or below your true baseline. Monthly variation is about 9.7%.

A single reading gives you a snapshot. A trend gives you a trajectory. If you are making dietary changes, starting a medication, or losing weight, you want to see whether your ApoB is actually moving in the right direction, and by how much. Get a baseline, retest in 3 to 6 months if you have made changes, and then at least annually. Two to three initial measurements, taken weeks apart, provide a reliable baseline.

The trend also protects you from overreacting to a single outlier. If your ApoB comes back higher than expected after a stressful week or an illness, the next draw will usually correct back toward your true level. Tracking over time separates real shifts from noise.

When Results Can Be Misleading

ApoB has a practical advantage over standard lipid panels: it does not require fasting. Even after a meal, more than 95% of circulating ApoB is the liver-produced form (ApoB-100), so eating before your blood draw will not meaningfully change your result. Variation across the day is also minimal, with levels fluctuating by only about 6.5%, so you do not need to draw blood at a specific time.

However, a few situations can produce misleading readings. Acute illness, surgery, and active infections suppress ApoB levels, sometimes substantially. If you have been sick in the past few weeks, your result may be falsely low. On the other end, corticosteroids (like prednisone) raise ApoB by boosting production in the liver. In one study, 43% of prednisone-treated patients had ApoB above 120 mg/dL compared to only 7% of controls. Untreated hypothyroidism also elevates ApoB, while hyperthyroidism lowers it.

Intense exercise can transiently push ApoB up by 8 to 9% in the 24 hours after a hard session. If you did a strenuous workout the day before your blood draw, your reading may be slightly inflated. For the most representative result, avoid intense exercise for 24 to 48 hours before testing, and ensure you are not in the middle of an acute illness.

Reduced kidney function is another confounder. ApoB-containing particles increase significantly as kidney filtration declines, with some studies showing a three-fold rise in people with the lowest kidney function. If your kidney markers are abnormal, your ApoB may be higher than it would otherwise be, and the clinical interpretation should account for that.